BLGO · Biolargo, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | $12.23M | - | - | - |
| Cost of Revenue | $4.36M | $9.93M | $6.08M | $3.03M | $1.43M | $1.20M |
| Gross Profit | $3.41M | $7.85M | $6.15M | $2.86M | $1.10M | $1.23M |
| R&D | $2.59M | $2.88M | $2.28M | $1.32M | $1.37M | $1.34M |
| SG&A | $11.77M | $9.30M | $8.06M | $6.73M | $6.17M | $7.47M |
| Total Operating Expenses | $18.26M | $12.18M | $10.73M | $8.25M | $7.54M | $8.81M |
| D&A | $145.0K | $155.0K | $103.0K | $45.0K | $20.0K | $58.0K |
| Operating Income | ($14.86M) | ($4.33M) | ($4.58M) | ($5.39M) | ($6.44M) | ($7.58M) |
| Interest Expense | $540.0K | $66.0K | $91.0K | $53.0K | $234.0K | $1.92M |
| Income Tax | - | $0 | - | - | - | - |
| Net Income | ($11.78M) | ($2.40M) | ($3.50M) | ($4.47M) | ($7.08M) | ($8.43M) |
| EPS - Basic | ($0.04) | ($0.01) | ($0.02) | ($0.03) | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.88M | $3.55M | $3.54M | $1.85M | $962.0K | $716.0K |
| Accounts Receivable | $615.0K | $3.17M | $2.61M | $1.06M | $513.0K | $484.0K |
| Inventory | $310.0K | $330.0K | $153.0K | $120.0K | $241.0K | $277.0K |
| Accounts Payable | $1.01M | $826.0K | $1.21M | $717.0K | $350.0K | $315.0K |
| Current Assets | $5.11M | $7.14M | $6.36M | $3.15M | $1.80M | $1.50M |
| Total Assets | $8.31M | $10.51M | $8.21M | $4.86M | $3.02M | $4.94M |
| Current Liabilities | $5.06M | $2.65M | $2.71M | $1.58M | $1.37M | $3.54M |
| Long-term Debt | $2.08M | $1.08M | $289.0K | $237.0K | $180.0K | $507.0K |
| Total Liabilities | $6.79M | $4.46M | $4.00M | $2.85M | $2.09M | $5.18M |
| Stockholders' Equity | $4.04M | $8.85M | $6.84M | $4.88M | $4.65M | $3.86M |
| Retained Earnings | ($161.28M) | ($149.50M) | ($147.10M) | ($143.59M) | ($139.12M) | ($132.04M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.30M) | ($3.21M) | ($2.37M) | ($2.76M) | ($3.94M) | ($4.15M) |
| Investing Cash Flow | $435.0K | ($1.32M) | ($478.0K) | ($271.0K) | ($34.0K) | ($123.0K) |
| Financing Cash Flow | $8.22M | $4.44M | $4.66M | $3.96M | $4.23M | $4.34M |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | 50.3% | - | - | - |
| Operating margin | - | - | -37.4% | - | - | - |
| EBITDA margin | - | - | -36.6% | - | - | - |
| Net margin | - | - | -28.7% | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | 18.7% | - | - | - |
| SG&A / Revenue | - | - | 65.9% | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -141.7% | -22.8% | -42.7% | -92.1% | -234.2% | -170.6% |
| Return on equity | -291.4% | -27.1% | -51.2% | -91.7% | -152.2% | -218.6% |
| Return on invested capital | - | -34.5% | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.01 | 2.70 | 2.35 | 2.00 | 1.31 | 0.42 |
| Quick ratio | 0.95 | 2.57 | 2.29 | 1.92 | 1.14 | 0.35 |
| Cash ratio | 0.77 | 1.34 | 1.31 | 1.17 | 0.70 | 0.20 |
| Leverage | ||||||
| Debt / Equity | 0.51 | 0.12 | 0.04 | 0.05 | 0.04 | 0.13 |
| Debt / Assets | 0.25 | 0.10 | 0.04 | 0.05 | 0.06 | 0.10 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -27.5x | -65.6x | -50.3x | -101.7x | -27.5x | -3.9x |
| Equity multiplier | 2.06 | 1.19 | 1.20 | 1.00 | 0.65 | 1.28 |
| Liabilities / Assets | 0.82 | 0.42 | 0.49 | 0.59 | 0.69 | 1.05 |
| Efficiency | ||||||
| Asset turnover | - | - | 1.49 | - | - | - |
| Inventory turnover | 14.06 | 30.08 | 39.71 | 25.23 | 5.93 | 4.35 |
| Days sales outstanding | - | - | 78d | - | - | - |
| Days inventory outstanding | 26d | 12d | 9d | 14d | 62d | 84d |
| Days payable outstanding | 85d | 30d | 73d | 86d | 89d | 95d |
| Cash conversion cycle | - | - | 14d | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | -56.6% | 27.6% | 115.4% | 159.0% | -10.2% | 34.1% |
| Operating income growth (YoY) | -243.0% | 5.4% | 15.0% | 16.3% | 15.1% | -13.2% |
| Net income growth (YoY) | -390.4% | 31.4% | 21.7% | 36.8% | 16.0% | 21.1% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -54.3% | 29.3% | 40.3% | 4.8% | 20.6% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Chemicals & Allied Products
Comparing BIOLARGO against the 5 most active filers in the same SIC group.